Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04325334
Other study ID # H19-01806
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2019
Est. completion date December 1, 2024

Study information

Verified date November 2023
Source University of British Columbia
Contact Natasha Krowchuk, BSc
Phone 604-822-7948
Email natasha.krowchuk@ubc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Knee osteoarthritis (OA) is a debilitating disease affecting millions of Canadians. Exercise is a core treatment for knee OA, and is advocated by all clinical guidelines. However, the safety of recreational running in the presence of knee OA is unclear. There are no studies available to provide direct data to appropriately inform runners and clinicians whether running should be advocated for joint health. Our research study will address this gap.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: ALL: - aged greater than 40 years - recreational runners who run at least twice per week for a total of at least 10 km, and have done so for a minimum of 12 months - comfortable running on a treadmill for 30 minutes. TFOA Group: - exhibit radiographic evidence of mild or moderate tibiofemoral osteoarthritis (TFOA) according to the Kellgren and Lawrence OA classification scale (grade = 2) - report knee pain on most days of the previous 3 months (during running and activities of daily living). Control Group: - free of any radiographic signs of TFOA according to the Kellgren and Lawrence scale (grade = 0) - pain free in both knees for the 12 months prior to recruitment. Exclusion Criteria: ALL: - any history of traumatic knee injury (fracture, severe sprain, meniscus injury) - presence of an inflammatory arthritic condition - presence of any health condition (other than OA in the TFOA group) affecting normal movement or precludes engaging in moderate to high impact activities such as running - use of any oral or injected corticosteroids or viscosupplementation in the previous 6 months - any history of surgery in either knee - standard contra-indications to magnetic resonance imaging (MRI).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Running volume increase
Participants will receive a 12-week running program to increase their running volume by approximately 10% per week on average, and in accordance with the "10% rule" advocated to minimize injury rates. For the purpose of this study, participants will run using their habitual technique - i.e. no specific instructions on 'how' to run will be provided; rather, they will simply be instructed on 'how much' to run.

Locations

Country Name City State
Canada Motion Analysis and Biofeedback Laboratory, The University of British Columbia Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline to 12 weeks in T2 relaxation time of the medial femoral cartilage T2 relaxation represents the time constant of the molecular motion of water in cartilage, which is influenced by the composition of collagen and specifically reflects changes to the extracellular matrix. This constant is assessed using MRI. Baseline, 12 weeks
Primary Change from Baseline to 12 weeks in T2 relaxation time of the medial tibial cartilage T2 relaxation represents the time constant of the molecular motion of water in cartilage, which is influenced by the composition of collagen and specifically reflects changes to the extracellular matrix. This constant is assessed using MRI. Baseline, 12 weeks
Primary Change from Baseline to 12 weeks in T2 relaxation time of the lateral femoral cartilage T2 relaxation represents the time constant of the molecular motion of water in cartilage, which is influenced by the composition of collagen and specifically reflects changes to the extracellular matrix. This constant is assessed using MRI. Baseline, 12 weeks
Primary Change from Baseline to 12 weeks in T2 relaxation time of the lateral tibial cartilage T2 relaxation represents the time constant of the molecular motion of water in cartilage, which is influenced by the composition of collagen and specifically reflects changes to the extracellular matrix. This constant is assessed using MRI. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in T1? relaxation time of the medial femoral cartilage T1? provides an indication of glycosaminoglycan concentration in cartilage assessed using MRI. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in T1? relaxation time of the medial tibial cartilage T1? provides an indication of glycosaminoglycan concentration in cartilage assessed using MRI. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in T1? relaxation time of the lateral femoral cartilage T1? provides an indication of glycosaminoglycan concentration in cartilage assessed using MRI. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in T1? relaxation time of the lateral tibial cartilage T1? provides an indication of glycosaminoglycan concentration in cartilage assessed using MRI. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee joint loading: peak knee adduction moment Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee joint loading: knee adduction moment impulse Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee joint loading: peak flexion moment Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee joint loading: flexion moment impulse Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee joint kinematics: peak knee flexion angle Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee joint kinematics: knee joint angle excursion Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in foot strike pattern Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in step rate Participants will run on an instrumented treadmill in their habitual running shoes while analyzed using three-dimensional motion analysis. Kinematic (joint angle) and kinetic (joint loading) data will be collected synchronously using high-speed digital cameras and treadmill-embedded force platforms. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee symptoms: Knee Osteoarthritis Outcome Score (KOOS) Validated questionnaire on symptoms and functional limitations related to knee osteoarthritis. The score is expressed in percentage (0-100), with 0 representing extreme knee problems and 100 representing no knee problems. Baseline, 12 weeks
Secondary Change from Baseline to 12 weeks in knee symptoms: Visual Analog Scale Knee pain during and after running will be assessed for each training. The minimum value is "No Pain" and the maximum value is "Worst Pain Imaginable". Each week of training will be averaged. Baseline to 12 weeks, averaged weekly
Secondary Change from Baseline to 12 weeks in weekly running distance Participants will record their weekly running distance using an online diary. Baseline to 12 weeks, averaged weekly
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT02905747 - The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis N/A
Not yet recruiting NCT02854176 - Somatosensory Stimulation in Knee Osteoarthritis Phase 2
Completed NCT03037489 - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients Phase 2